| 5.05 0.06 (1.2%) | 04-22 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 6 | 1-year : | 6.31 |
| Resists | First : | 5.14 | Second : | 5.4 |
| Pivot price | 5.03  |
|||
| Supports | First : | 4.71 | Second : | 3.91 |
| MAs | MA(5) : | 4.95 |
MA(20) : | 5.03 |
| MA(100) : | 7.01 |
MA(250) : | 8.45 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 35.8 |
D(3) : | 24.9 |
| RSI | RSI(14): 44.9 |
|||
| 52-week | High : | 12.43 | Low : | 4.71 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AUPH ] has closed below upper band by 44.4%. Bollinger Bands are 75.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 22 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.07 - 5.09 | 5.09 - 5.11 |
| Low: | 4.86 - 4.89 | 4.89 - 4.91 |
| Close: | 5 - 5.05 | 5.05 - 5.09 |
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Fri, 19 Apr 2024
Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Movies UK
Thu, 18 Apr 2024
Aurinia Pharmaceuticals (NASDAQ:AUPH) Sets New 1-Year Low at $4.82 - MarketBeat
Tue, 16 Apr 2024
Aurinia Pharmaceuticals to Present at Investor Conference - TipRanks.com - TipRanks
Tue, 09 Apr 2024
Aurinia Pharma to Connect at Healthcare Investor Event - TipRanks.com - TipRanks
Sun, 07 Apr 2024
When Will Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Breakeven? - Yahoo Finance
Tue, 02 Apr 2024
individual investors who own 56% along with institutions invested in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ... - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 145 (M) |
| Shares Float | 132 (M) |
| Held by Insiders | 7.4 (%) |
| Held by Institutions | 38.5 (%) |
| Shares Short | 12,240 (K) |
| Shares Short P.Month | 12,100 (K) |
| EPS | -0.55 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.63 |
| Profit Margin | -44.5 % |
| Operating Margin | -52.8 % |
| Return on Assets (ttm) | -10.6 % |
| Return on Equity (ttm) | -20 % |
| Qtrly Rev. Growth | 58.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.21 |
| EBITDA (p.s.) | -0.52 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -33 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -9.36 |
| PEG Ratio | 0 |
| Price to Book value | 1.92 |
| Price to Sales | 4.16 |
| Price to Cash Flow | -21.83 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|